Arbutus Biopharma Corp Company Profile (NASDAQ:ABUS)

About Arbutus Biopharma Corp

Arbutus Biopharma Corp logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABUS
  • CUSIP:
Key Metrics:
  • Previous Close: $2.65
  • 50 Day Moving Average: $2.66
  • 200 Day Moving Average: $3.08
  • 52-Week Range: $54,841,000.00 - $2.35
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.56
  • P/E Growth: 0.00
  • Market Cap: $145.33M
  • Outstanding Shares: 54,841,000
  • Beta: 1.24
Profitability:
  • Net Margins: -1,192.92%
  • Return on Equity: -8.50%
  • Return on Assets: -6.68%
Debt:
  • Current Ratio: 18.09%
  • Quick Ratio: 18.09%
Additional Links:
Companies Related to Arbutus Biopharma Corp:

Analyst Ratings

Consensus Ratings for Arbutus Biopharma Corp (NASDAQ:ABUS) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $6.25 (135.85% upside)

Analysts' Ratings History for Arbutus Biopharma Corp (NASDAQ:ABUS)
Show:
DateFirmActionRatingPrice TargetDetails
2/1/2017WedbushLower Price TargetOutperform$13.00 -> $10.00View Rating Details
1/9/2017Bloom BurtonUpgradeAccumulate -> BuyView Rating Details
12/13/2016Chardan CapitalDowngradeBuy -> Neutral$4.00 -> $3.00View Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details
8/21/2016William BlairReiterated RatingOutperformView Rating Details
8/17/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
12/21/2015Royal Bank of CanadaLower Price Target$20.00 -> $12.00View Rating Details
6/16/2015Maxim GroupLower Price TargetHold -> Buy$27.00 -> $14.00View Rating Details
3/30/2015NomuraInitiated CoverageBuy$32.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Arbutus Biopharma Corp (NASDAQ:ABUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
5/4/2016Q1($0.39)($0.19)ViewN/AView Earnings Details
3/9/2016Q4($0.41)($0.06)ViewN/AView Earnings Details
11/5/2015($0.31)($0.42)ViewN/AView Earnings Details
8/5/2015Q2($0.26)($0.20)ViewN/AView Earnings Details
3/13/2015($0.32)($0.27)ViewN/AView Earnings Details
11/6/2014Q314($0.31)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/13/2014Q214($0.26)($0.28)$3.72 million$1.80 millionViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arbutus Biopharma Corp (NASDAQ:ABUS)
Current Year EPS Consensus Estimate: $-3.68 EPS
Next Year EPS Consensus Estimate: $-1.70 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.38)($0.36)($0.37)
Q2 20162($0.40)($0.35)($0.38)
Q3 20162($0.41)($0.39)($0.40)
Q4 20162($0.39)($0.37)($0.38)
Q1 20171($0.38)($0.38)($0.38)
Q2 20171($0.40)($0.40)($0.40)
Q3 20171($0.41)($0.41)($0.41)
Q4 20171($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arbutus Biopharma Corp (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Arbutus Biopharma Corp (NASDAQ:ABUS)
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 61.24%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Arbutus Biopharma Corp (NASDAQ:ABUS)
DateHeadline
News IconMomentum Watch on Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) - Benton Bulletin (NASDAQ:ABUS)
bentonbulletin.com - February 25 at 3:15 PM
News IconLooking at the Numbers for Arbutus Biopharma Corp (ABUS) - The Standard (NASDAQ:ABUS)
6milestandard.com - February 24 at 3:16 PM
News IconAre Analysts Optimistic About Where Arbutus Biopharma Corp (NASDAQ:ABUS) is Heading? - Winfield Review (NASDAQ:ABUS)
winfieldreview.com - February 24 at 9:31 AM
News IconAnalysts Take: Arbutus Biopharma Corp (NASDAQ:ABUS) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:ABUS)
aikenadvocate.com - February 23 at 3:17 PM
News IconArbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP (NASDAQ:ABUS)
www.bctechnology.com - February 20 at 3:17 PM
News IconChecking on Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) - Providence Standard (NASDAQ:ABUS)
providencestandard.com - February 18 at 3:16 PM
News IconShare Inspection for Arbutus Biopharma Corporation (ABUS) - Baxter Review (NASDAQ:ABUS)
baxternewsreview.com - February 16 at 3:16 PM
News IconArbutus Biopharma Corporation NASDAQ:ABUS Sees Unusual Volatility in Session - Aiken Advocate (NASDAQ:ABUS)
aikenadvocate.com - February 16 at 3:16 PM
News IconIs The Sell-Side Predicting That Arbutus Biopharma Corp (NASDAQ:ABUS) Will Move Higher? - Winfield Review (NASDAQ:ABUS)
winfieldreview.com - February 16 at 6:00 AM
bizjournals.com logoDoylestown biopharm firm granted injunction over licensing dispute - Philadelphia Business Journal (NASDAQ:ABUS)
www.bizjournals.com - February 11 at 1:20 AM
bizjournals.com logoDoylestown biopharm firm granted injunction over licensing dispute (NASDAQ:ABUS)
www.bizjournals.com - February 10 at 3:18 PM
globenewswire.com logoArbutus to Participate in Upcoming Investor Conferences Nasdaq ... - GlobeNewswire (press release) (NASDAQ:ABUS)
globenewswire.com - February 10 at 1:14 AM
feeds.benzinga.com logoArbutus to Participate in Upcoming Investor Conferences (NASDAQ:ABUS)
feeds.benzinga.com - February 9 at 5:16 PM
News IconChart Watch for Arbutus Biopharma Corporation (NASDAQ:ABUS) - Davidson Register (NASDAQ:ABUS)
davidsonregister.com - February 9 at 3:12 PM
seekingalpha.com logoArbutus Biopharma Corp (ABUS) (NASDAQ:ABUS)
seekingalpha.com - February 8 at 3:21 PM
finance.yahoo.com logoArbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology (NASDAQ:ABUS)
finance.yahoo.com - February 8 at 3:21 PM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 8-K, Other Events (NASDAQ:ABUS)
biz.yahoo.com - February 8 at 3:21 PM
News IconStock Tripped Up Out of The Gate: Arbutus Biopharma Corporation (NASDAQ:ABUS) - Aiken Advocate (NASDAQ:ABUS)
aikenadvocate.com - February 7 at 3:17 PM
live-pr.com logoArbutus Biopharma Corporation (ABUS) - Financial and Strategic SWOT Analysis Review - New Report Available (NASDAQ:ABUS)
www.live-pr.com - February 2 at 8:16 PM
News IconMA Watch on Shares of Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - February 2 at 3:16 PM
News IconAre Analysts Forecasting a Near-Term Upswing For Arbutus Biopharma Corp (NASDAQ:ABUS)? - Wall Street Beacon (NASDAQ:ABUS)
wsbeacon.com - February 1 at 3:22 PM
News IconIncrease in Volatility Draws Attention to Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) - Wall Street Beacon (NASDAQ:ABUS)
wsbeacon.com - February 1 at 3:22 PM
News IconWhat are the Technical Charts Saying About Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - February 1 at 3:22 PM
News IconIs Major Move Coming For Arbutus Biopharma Corp (ABUS) After This Wedge Down? (NASDAQ:ABUS)
randolphguide.com - February 1 at 1:20 AM
News IconStock ready to Pivot? Focus on Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) - Prospect Journal (NASDAQ:ABUS)
prospectjournal.com - January 31 at 3:18 PM
News IconTechnical Watch on These Shares: Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - January 31 at 3:18 PM
News IconInvestor Circle: Watching the Numbers on Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) - Gilbert Daily (NASDAQ:ABUS)
gilbertdaily.com - January 30 at 8:28 PM
News IconInvestor Corner: Checking the Charts for Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - January 30 at 3:27 PM
News IconEarnings in Full Force, Analysts Take Aim at Arbutus Biopharma Corp (NASDAQ:ABUS) - Wall Street Beacon (NASDAQ:ABUS)
wsbeacon.com - January 27 at 3:31 PM
News IconStock Looking Bearish Out Of The Gate, Gapping Down: Arbutus Biopharma Corporation (NASDAQ:ABUS) - Aiken Advocate (NASDAQ:ABUS)
aikenadvocate.com - January 27 at 3:30 PM
News IconHigh Volatility Creating Buzz Mid-Session For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Wall Street Beacon (NASDAQ:ABUS)
wsbeacon.com - January 27 at 3:30 PM
News IconWhat The Charts Are Saying About Arbutus Biopharma Corporation (NASDAQ:ABUS) - Gilbert Daily (NASDAQ:ABUS)
gilbertdaily.com - January 26 at 3:28 PM
News IconStock Update: Estimates & Target in Focus for Arbutus Biopharma Corp (NASDAQ:ABUS) - Aiken Advocate (NASDAQ:ABUS)
aikenadvocate.com - January 26 at 3:28 PM
News IconTracking Williams %R for Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - January 26 at 3:28 PM
News IconRSI Review on Shares of Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - January 25 at 3:19 PM
News IconFollowing FCF Scores for Arbutus Biopharma Corporation (NASDAQ:ABUS) - Gilbert Daily (NASDAQ:ABUS)
gilbertdaily.com - January 25 at 3:19 PM
News IconTrading Radar: Zooming in on Shares of Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - January 24 at 8:38 PM
News IconErratic Volume Stretches This Stock Mid-Session: Arbutus Biopharma Corporation (NASDAQ:ABUS) - Wall Street Beacon (NASDAQ:ABUS)
wsbeacon.com - January 24 at 8:38 PM
News IconKeeping an Eye on Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) - Gilbert Daily (NASDAQ:ABUS)
gilbertdaily.com - January 24 at 3:36 PM
News IconMA Levels in Review for Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - January 23 at 8:18 PM
News IconStock Spotlight: Zooming in on Shares of Arbutus Biopharma ... - Gilbert Daily (NASDAQ:ABUS)
gilbertdaily.com - January 23 at 3:17 PM
News IconIs There a Catalyst Out There For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Prospect Journal (NASDAQ:ABUS)
prospectjournal.com - January 20 at 3:12 PM
News IconSell-side Consensus Sees Arbutus Biopharma Corp (NASDAQ:ABUS) Going Where Near-Term? - Aiken Advocate (NASDAQ:ABUS)
aikenadvocate.com - January 19 at 3:21 PM
News IconTrading Review: Technical Survey on Shares of Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - January 19 at 3:21 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Arbutus Biopharma Corp (NASDAQ:ABUS) - Wall Street Beacon (NASDAQ:ABUS)
wsbeacon.com - January 18 at 3:39 PM
News IconTrend Strength Monitor on Shares of Arbutus Biopharma Corporation (ABUS) - Sherwood Daily (NASDAQ:ABUS)
sherwooddaily.com - January 18 at 3:39 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Arbutus Biopharma Corporation (NASDAQ:ABUS) - Wall Street Beacon (NASDAQ:ABUS)
wsbeacon.com - January 18 at 3:39 PM
News IconCan This Stock Pick Up Any Momentum: Arbutus Biopharma Corporation (NASDAQ:ABUS) - Prospect Journal (NASDAQ:ABUS)
prospectjournal.com - January 18 at 3:39 PM
News IconStock Momentum Skidding to a Halt For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Wall Street Beacon (NASDAQ:ABUS)
wsbeacon.com - January 17 at 8:18 PM
News IconWith Profitability At The Forefront, Is This Stock a Top Pick: Arbutus Biopharma Corporation (NASDAQ:ABUS) - Wall Street Beacon (NASDAQ:ABUS)
wsbeacon.com - January 17 at 3:16 PM

Social

What is Arbutus Biopharma Corp's stock symbol?

Arbutus Biopharma Corp trades on the NASDAQ under the ticker symbol "ABUS."

Where is Arbutus Biopharma Corp's stock going? Where will Arbutus Biopharma Corp's stock price be in 2017?

6 brokerages have issued 12 month price objectives for Arbutus Biopharma Corp's stock. Their forecasts range from $3.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $6.25 in the next year.

When will Arbutus Biopharma Corp announce their earnings?

Arbutus Biopharma Corp is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

What are analysts saying about Arbutus Biopharma Corp stock?

Here are some recent quotes from research analysts about Arbutus Biopharma Corp stock:

  • According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (2/17/2017)

  • Wedbush analysts commented, "We see ABUS as well positioned with data from three clinical assets set to provide positive news-flow in 2017. We believe recently presented preclinical data demonstrating synergy of these assets support ABUS's strategy of an effective combination therapy for HBV. We also see additional upside to shares from the mid:17 readout of Alnylam's (ALNY, not covered) Ph 3 study of patisiran, as well as the potential for additional partnerships around ABUS's attractive LNP platform." (1/31/2017)

Who owns Arbutus Biopharma Corp stock?

Arbutus Biopharma Corp's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ladenburg Thalmann Financial Services Inc. (9.66%), Armistice Capital LLC (3.54%), Falcon Edge Capital LP (3.02%) and Oxford Asset Management (0.29%).

Who sold Arbutus Biopharma Corp stock? Who is selling Arbutus Biopharma Corp stock?

Arbutus Biopharma Corp's stock was sold by a variety of institutional investors in the last quarter, including Falcon Edge Capital LP.

Who bought Arbutus Biopharma Corp stock? Who is buying Arbutus Biopharma Corp stock?

Arbutus Biopharma Corp's stock was bought by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc., Armistice Capital LLC and Oxford Asset Management.

How do I buy Arbutus Biopharma Corp stock?

Shares of Arbutus Biopharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Arbutus Biopharma Corp stock cost?

One share of Arbutus Biopharma Corp stock can currently be purchased for approximately $2.65.

Arbutus Biopharma Corp (NASDAQ:ABUS) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)

Earnings History Chart

Earnings by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)

Dividend History Chart

Dividend Payments by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)

Last Updated on 2/26/2017 by MarketBeat.com Staff